Prelude Therapeutics (PRLD) AI Stock Analysis

• Market Cap: $174.94M
• Dividend Yield: N/A
• Average Volume (3M): 256.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 250.00%
• EPS Growth: 15.15%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 43,765,010
• 10 Day Avg. Volume: 194,393
• 30 Day Avg. Volume: 256,051
• PEG Ratio: 0.04
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 16.87
• P/FCF Ratio: -5.74
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 13.41
• Enterprise Value/Gross Profit: 13.98
• Enterprise Value/Ebitda: -1.19
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.42
• Revenue Forecast (FY): $50.00M

• Rating: 61 Neutral
• Price Target: $3.50 ▲(42.86% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

Score is held back most by weak financial performance (large ongoing losses and cash burn despite improving trends and low leverage). Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and a constructive earnings-call outlook driven by the Incyte partnership and defined 2026 clinical catalysts, while valuation remains difficult to justify with negative earnings and no dividend.

Positive Factors

Strategic partnership with Incyte

The exclusive option agreement with Incyte provides substantial non-dilutive capital and third-party validation, materially de-risking development financing for lead programs. This funding and strategic alignment support multi-year R&D execution and reduces near-term financing pressure while enabling milestone-focused development.

Regulatory progress (IND clearance)

FDA IND clearance transitions the JAK2V617F program from preclinical to clinical development, structurally advancing the company toward human proof-of-concept data. Clinical entry shortens the timeline to value-inflection events and solidifies program credibility with partners, payors, and future investors over the medium term.

Near-term cash runway

A cash balance north of $100M and guidance to fund operations into Q2 2027 gives Prelude a multi-quarter runway to initiate Phase 1 studies and hit early clinical milestones. This liquidity window supports disciplined development pacing and negotiation flexibility for partnerships or milestone-driven non-dilutive capital.

Negative Factors

High cash burn & negative free cash flow

Sustained negative operating and free cash flow indicates the business cannot self-fund development and remains reliant on external financing or partner payments. Persistent burn increases dilution risk, forces opportunistic deal-making, and limits flexibility to fund additional programs if clinical timelines slip.

Weakened balance sheet and declining equity

A sharp decline in equity and assets over 2023–2025 reduces financial resilience and the company's capacity to absorb setbacks. With a thinner asset base, Prelude faces higher vulnerability to adverse trial results or slower milestones, increasing the likelihood of dilution or accelerated partner dependence to sustain operations.

Clinical timing & competitive risk

Delayed clinical starts leave a prolonged period before value-creating data, giving incumbents time to entrench and new competitors to enter. Long timelines amplify execution risk, require sustained funding, and make differentiation versus larger players harder, pressuring potential adoption if approvals are achieved later.

Prelude Therapeutics Business Overview & Revenue Model

Company Description

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

How the Company Makes Money

Prelude Therapeutics primarily generates revenue, when applicable, through collaboration and licensing arrangements (e.g., upfront payments, research funding, milestone payments tied to development/regulatory/commercial events, and potential royalties on partner sales). As a clinical-stage company, it typically does not have recurring product sales revenue unless one of its drug candidates receives regulatory approval and is commercialized, in which case revenue would come from product sales (or royalties/profit-sharing if commercialized via a partner). Specific current partners, deal terms, and the mix of revenue components are null.

Prelude Therapeutics Financial Statement Overview

Summary

Early revenue traction and improving losses/cash burn in 2025 are positives, but the company remains deeply unprofitable with sizable ongoing operating losses and negative free cash flow. Low leverage helps, yet the sharp decline in equity/assets over 2023–2025 underscores continued funding/runway risk.

Income Statement

Revenue has begun to emerge and improve (up ~16% in 2025 vs. 2024, after ~$7.0M in 2024 and $0 in 2021–2023), but the business remains deeply unprofitable. Losses are large and persistent, with EBIT around -$105M in 2025 and net income around -$99.5M in 2025 (still a significant improvement vs. -$127.2M in 2024). Overall, the trajectory is modestly better, but profitability and scale are still key weaknesses.

Balance Sheet

Leverage is modest, with total debt of ~$17.8M against equity of ~$68.6M in 2025 (and a low debt-to-equity ratio of ~0.14 in 2024 and ~0.07 in 2023). However, the balance sheet has weakened materially over time as equity declined from ~$237.1M (2023) to ~$131.5M (2024) to ~$68.6M (2025), reflecting ongoing losses. Assets have also stepped down (from ~$277.7M in 2023 to ~$141.3M in 2025), which reduces financial flexibility despite low debt.

Cash Flow

Cash burn remains heavy, with operating cash flow of about -$56.3M in 2025 and free cash flow of about -$56.4M. The burn rate did improve substantially versus 2024 (operating cash flow about -$102.9M and free cash flow about -$103.7M), but cash generation is still negative and dependent on external funding. Historically, free cash flow has generally tracked net losses closely, underscoring limited self-funding capacity at this stage.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.50M	12.14M	7.00M	0.00	0.00	0.00
Gross Profit	10.07M	0.00	7.00M	0.00	0.00	0.00
EBITDA	-118.57M	-104.57M	-137.94M	-131.11M	-122.22M	-112.82M
Net Income	-111.77M	-99.50M	-127.17M	-121.83M	-115.44M	-111.69M
Balance Sheet
Total Assets	94.75M	141.31M	175.51M	277.67M	220.50M	305.10M
Cash, Cash Equivalents and Short-Term Investments	54.96M	103.21M	133.61M	232.94M	201.73M	291.23M
Total Debt	17.85M	17.79M	18.02M	16.89M	1.83M	1.74M
Total Liabilities	36.22M	72.68M	44.06M	40.58M	25.06M	19.20M
Stockholders Equity	58.53M	68.64M	131.46M	237.09M	195.44M	285.90M
Cash Flow
Free Cash Flow	-100.28M	-56.37M	-103.65M	-110.58M	-86.75M	-85.85M
Operating Cash Flow	-100.17M	-56.30M	-102.89M	-107.06M	-83.73M	-83.53M
Investing Cash Flow	135.92M	53.46M	90.19M	-34.65M	81.69M	-263.80M
Financing Cash Flow	-162.00K	24.82M	-120.00K	136.40M	815.00K	164.90M

Prelude Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Positive. The current price of 2.45 is below the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.42, and above the 200-day MA of 1.52, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 61.64 is Neutral, neither overbought nor oversold. The STOCH value of 71.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRLD.

Prelude Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	61 Neutral	$174.94M	-1.39	-103.99%	―	250.00%	15.15%
PMVP	53 Neutral	$86.93M	-0.84	-59.07%	―	―	-58.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GANX	46 Neutral	$112.69M	-2.93	-341.33%	―	―	42.29%
PSTV	40 Underperform	$52.66M	-4.15	335.91%	―	-8.16%	22.44%

Prelude Therapeutics Corporate Events

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

Prelude Therapeutics reported full-year 2025 financial results on March 10, 2026, and outlined a 2026 program roadmap centered on its JAK2V617F and KAT6A programs. The company ended 2025 with $106.4 million in cash and equivalents, expects its cash runway to extend into the second quarter of 2027, and reduced its annual net loss to $99.5 million as R&D and G&A expenses declined.

The U.S. FDA cleared the IND for lead JAK2V617F inhibitor PRT12396 in early 2026, with a Phase 1 trial in high-risk polycythemia vera and myelofibrosis patients expected to start by the second quarter of 2026 under an exclusive option agreement with Incyte. Prelude also advanced its highly selective oral KAT6A degrader PRT13722 toward a planned mid-2026 IND filing and second-half 2026 Phase 1 start, while expanding its degrader payload DAC collaboration with AbCellera and progressing an early-stage, wholly owned mutated calreticulin DAC program for CALR-mutant myeloid malignancies.

The most recent analyst rating on (PRLD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.

Prelude Therapeutics Wins FDA IND Clearance for PRT12396

On February 3, 2026, Prelude Therapeutics announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for PRT12396, a mutant-selective JAK2V617F inhibitor designed to treat certain myeloproliferative neoplasms, allowing the company to proceed with a Phase 1 study and positioning the drug as a potential new targeted option for patients with polycythemia vera and myelofibrosis. The open-label, multi-center trial, expected to begin dosing patients by the second quarter of 2026, marks a key milestone in Prelude’s strategic pivot toward its JAK2 and KAT6 programs and advances an asset that sits under an exclusive option agreement with Incyte, underscoring the company’s ambition to reshape the treatment landscape in myeloproliferative neoplasms and strengthen its standing in precision oncology.

The most recent analyst rating on (PRLD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.

Prelude Therapeutics unveils strategic investor presentation on pipelines

On January 9, 2026, Prelude Therapeutics began using a new corporate investor presentation outlining its strategy to advance two highly differentiated programs: JAK2V617F mutant-selective JH2 inhibitors for myeloproliferative neoplasms and first-in-class, highly selective oral KAT6A degraders for ER-positive breast cancer and other tumors. The materials highlight recently disclosed preclinical data showing potent, mutant-selective activity of its JAK2V617F inhibitors, positioning them as potential disease-modifying therapies in a large and growing market now dominated by first-generation agents such as ruxolitinib, and describe a planned Phase 1 program as well as an exclusive option agreement with Incyte announced in November 2025 that provides significant capital to support the JAK2V617F and KAT6A pipelines, alongside ongoing degrader payload discovery and partnering efforts.

The most recent analyst rating on (PRLD) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.